Literature DB >> 15247755

Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone.

R Shabsigh1, J M Kaufman, C Steidle, H Padma-Nathan.   

Abstract

PURPOSE: We compare the efficacy of testosterone gel (T-gel) versus placebo as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone.
MATERIALS AND METHODS: A randomized, placebo controlled, double-blind, parallel group, multicenter study was performed. A total of 75 hypogonadal men (18 to 80 years old, morning serum total testosterone 400 ng/dl or less) with confirmed lack of response to sildenafil monotherapy were randomized (1:1) to receive a daily dose of 1% T-gel or 5 gm placebo gel as adjunctive therapy to 100 mg sildenafil during a 12-week period. Subjects were evaluated for sexual function, primarily based on the International Index of Erectile Function (IIEF), quality of life and serum testosterone levels at baseline and weeks 4, 8 and 12.
RESULTS: Testosterone treated subjects had greater improvement in erectile function compared to those who received placebo, reaching statistical significance at week 4 (4.4 vs 2.1, p = 0.029, 95.1% CI 0.3, 4.7). Similar trends were observed for improvements in orgasmic function, overall satisfaction, total IIEF score and percentage of IIEF responders. T-gel significantly (p < or =0.004) increased total and free testosterone levels throughout the study, although no significant correlations were made between testosterone levels and the IIEF at end point.
CONCLUSIONS: T-gel taken with sildenafil may be beneficial in improving erectile function in hypogonadal men with erectile dysfunction who are unresponsive to sildenafil alone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247755     DOI: 10.1097/01.ju.0000132389.97804.d7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  46 in total

1.  Current Diagnosis and Management of Erectile Dysfunction.

Authors:  Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2014-09

Review 2.  Andropause: is the emperor wearing any clothes?

Authors:  S H Tariq; M T Haren; M J Kim; J E Morley
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

3.  Men's aging and sexual disorders: an update on diagnosis and treatment.

Authors:  Alvaro Morales
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

4.  Extending the rationale of combination therapy to unresponsive erectile dysfunction.

Authors:  Christopher Reece; Rajeev Kumar; Diedre Nienow; Ajay Nehra
Journal:  Rev Urol       Date:  2007

Review 5.  Androgens are fundamental in the maintenance of male sexual health.

Authors:  Alvaro Morales
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

Review 6.  Combination therapy for erectile dysfunction: an update review.

Authors:  Rohit R Dhir; Hao-Cheng Lin; Steven E Canfield; Run Wang
Journal:  Asian J Androl       Date:  2011-03-21       Impact factor: 3.285

7.  Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review.

Authors:  Naif Alhathal; Ahmed M Elshal; Serge Carrier
Journal:  Can Urol Assoc J       Date:  2012-08       Impact factor: 1.862

Review 8.  A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial.

Authors:  M Spitzer; S Basaria; T G Travison; M N Davda; L DeRogatis; S Bhasin
Journal:  Andrology       Date:  2013-03-15       Impact factor: 3.842

Review 10.  The use of phosphodiesterase 5 inhibitors with concomitant medications.

Authors:  G Corona; E Razzoli; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.